GLAND2,950.00

Gland Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAUROPHARMAPPLPHARMASYNGENEWOCKPHARMAASTERDMCOHANCELALPATHLABMcap ₹48,604 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)298.77311.84284.19284.19
Receivable Days (DSO)100.4398.55107.35107.35
Payable Days (DPO)155.72151.81135.89134.05
Cash Conversion Cycle (days)243.48258.58255.65257.49
Working Capital Turnover1.331.081.091.14
Asset Turnover0.530.500.510.51
Cash Conversion (CFO/Net Income)1.291.311.001.00
CFO/EBITDA0.750.720.630.63
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.